

SETTLEMENTS OF ACCOUNTS

From 1st April 2025
to 31st March 2026

Concord Biotech Japan K.K.

BALANCE SHEETS

As at 31st March 2026

CONCORD BIOTECH JAPAN K.K.

JPY

Assets		Liabilities	
<u>Current assets</u>	29,20,67,395	<u>Current liabilities</u>	5,44,92,348
Cash and deposit	12,97,08,957	Accounts payable-trade	3,03,05,000
Promissory notes [Receivable]	4,00,40,000	Short-term borrowings	2,16,801
Account receivable	6,00,60,000	Accounts payable	14,74,970
Allowance for doubtful accounts	-10,01,000	Accrued corporate taxes	51,36,200
Product Inventory	6,17,15,959	Consumption tax payable	1,53,67,400
Advance payments	11,25,850	Deposits payable	19,91,977
Prepaid expenses	4,17,629	<u>Long-term liabilities</u>	6,66,82,000
		Long-term borrowings	6,66,82,000
		Liabilities total:	12,11,74,348
<u>Fixed assets</u>	48,00,058	<u>Net Equity</u>	
<u>Fixed assets</u>	3,64,278	<u>Stockholders equity</u>	17,56,93,105
Bulidings and other facilities	1,64,700	Capital	2,00,00,000
Machinery and equipment	1	Accumulated earnings	15,56,93,105
Pooled low-value assets (depreciated over 3 years)	1,99,577	Other accumulated earnings	15,56,93,105
<u>Investment and other assets</u>	44,35,780	Brought down accumulated earnings	15,56,93,105
Capital	10,000	(Net gain of current period)	1,15,66,408
Guarantee deposits	44,25,780	Net equity total	17,56,93,105
Asset total:	29,68,67,453	Liabilities and net equity total:	29,68,67,453

Authorised Signatory

Mr. Devang Bhatt

Director

INCOME STATEMENT

From 1st April 2025 to 31st March 2026

Kadera Yakuhin Limited

JPY

<u>Net sales</u>		
Amount of sales	39,83,80,000	
Overseas sales	29,40,00,000	
Net sales total		69,23,80,000
<u>Cost of sales</u>		
Opening [Initial] Inventory	16,95,18,269	
Imported Purchases	23,16,80,270	
Import charges	2,57,563	
Import inspection	1,78,565	
Export charges	2,58,759	
Overseas purchases	27,04,80,000	
Total	67,23,73,426	
Closing [End] inventory	6,17,15,959	
Cost of sales		61,06,57,467
Gross profit		8,17,22,533
<u>Selling, general & administrative expenses</u>		
Total of selling, general & administrative expenses		6,67,76,748
Sales gain		1,49,45,785
<u>Non-operating gain</u>		
Interest received	20,070	
Divident received	250	
Miscellaneous income	75,472	
Non-operating gain Total		95,792
<u>Non-operating loss</u>		
Interest paid	13,09,651	
Discount on Promissory Notes (Receivable)	47,718	
Non-operating loss Total		13,57,369
Ordinary gain		1,36,84,208
<u>Other Income</u>		
Reversal of allowance for doubtful accounts	30,18,400	
Other Income Total		30,18,400
Profit before tax		1,67,02,608
Income tax		51,36,200
Net Profit		1,15,66,408

Authorised Signatory
Mr. Devang Bhatt
Director

Selling, General & Administrative Expenses

From 1st April 2025 to 31st March 2026

CONCORD BIOTECH JAPAN K.K.

JPY

Payments for directors, A.Sato and Utako Sato	2,24,10,000	
Salary	2,78,40,024	
Contribution to Health Insurance & Pension Fund	24,21,826	
Welfare expense	62,049	
Employee training expenses	13,637	
Transportation	46,590	
Advertising expenses (CPhI Japan)	18,03,000	
Customer entertainment expenses	32,316	
Meeting expenses [with customers]	1,965	
Traveling expenses	20,18,417	
Communications	2,13,733	
Sales promotion expenses (PHARMA JAPAN WEB 2024 & 2025)	2,70,000	
Office Supplies [like Printing & Stationery etc.]	8,32,739	
Office Supplies [Working Reference Standards]	2,07,630	
Utilities	1,95,562	
Books and subscription cost	30,000	
Bank Charges	5,28,107	
Professional Fees - Market Research (a large one-time expenditure for market research services on the drug for Atopic diseases)	15,00,000	
Drug regulatory expenses	45,200	
Payments to Consultants	6,14,000	
Depreciation expenses	1,49,508	
Office rent	45,01,721	
Corporate Taxes, Stamp Duty on Promissory Notes and Others	37,724	
Provision of allowance for doubtful accounts	10,01,000	
Total:		6,67,76,748